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Background: Parkinson’s disease (PD) eventually leads to severe functional decline and 
dependence. Specialized care units for PD patients in need of permanent care are lacking.
Methods: Patients with severe PD are referred to the PD permanent care unit harboring 30 patients 
with specialized medical and health care provided by trained staff. Patients need to have   intensive 
medical and care needs, and be no longer able to stay at home or at an ordinary institution. 
A written and continuously reviewed care plan is made for each patient at admission, with the 
overriding aim to preserve quality of life and optimize functionality.
Results: After five years, the PD permanent care unit has cared for 70 patients (36 men and 
34 women) with a mean age of 76.6 years and a mean duration of Parkinsonism of 11.8 years. 
Hoehn and Yahr severity of disease was 3.7, cognition was 25.3 (Mini-Mental State Examina-
tion), and the mean daily levodopa dose was 739 mg. The yearly fatality rate was seven, and 
the mean duration of stay was 26.9 months. Only five patients moved out from the unit.
Conclusion: A specially designed and staffed care unit for Parkinsonism patients seems to fill 
a need for patients and caregivers, as well as for social and health care authorities. This model 
is sensitive to the changing needs and capacities of patients, ensuring that appropriate services 
are available in a timely manner. There was a rather short duration of patient stay and remaining 
life span after admission to the unit. Despite the chronic/palliative state of patients at the PD 
permanent care unit, there are many therapeutic options, with the overriding objective being to 
allow the patients to end their days in a professional and comfortable environment.
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Introduction
The most common neurodegenerative movement disorder is Parkinson’s disease (PD), 
eventually leading to severe functional decline and dependence.1 During   disease progres-
sion, patients develop not only motor complications, like fluctuations and dyskinesia, 
but also nonmotor symptoms from many organs.2,3 These nonmotor symptoms are 
those that do not traditionally count as PD symptoms, but are receiving more interest 
in recent years because PD today is recognized as a multisystem brain disorder. The 
longer the duration of disease, the more the accumulation of these symptoms, which 
are often more devastating to patients than the motor symptoms. Neuropsychiatric 
symptoms like nightmares, paranoid ideas, hallucinations, and, ultimately, psychosis, 
often accompanied by cognitive decline, may appear.4 These symptoms are often very 
troublesome to the patient as well as to the caregiver, and are sometimes so difficult to 
treat and cope with, that affected patients are eventually institutionalized.5 This occurs 
even if the patients have devoted caregivers, as well as formal home help services.
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From disease onset and/or diagnosis, most patients are 
treated and cared for at outpatient departments. However, 
with PD being a progressive disorder, the worsening of and 
onset of new symptoms increases the need for outpatient 
visits, temporary hospital stays, home help, and respite care. 
It is evident that PD patients, unlike many other vulnerable 
patient groups, eg, those with Alzheimer’s disease or stroke, 
are often excluded from permanent stay in special care units. 
Such a unit could be an appropriate site when the disease is 
at an end-stage and palliative phase, the caregivers are no 
longer able to care for the patient, and more home help is 
not possible or adequate. This should be appropriate because 
the view of palliative care is now broader, and includes care 
for those patients in whom the consequences of their illness 
require treatment, regardless of the prognosis of the patient.6 
Thus, palliation is not the same as end-of-life care, care tar-
geted for cancer patients, or patients with a bad prognosis. 
When it comes to complex neurodegenerative diseases like 
PD, it is difficult to use prognosis estimates as determining 
factors for referrals to palliative care,7 and even if there is a 
need for palliative care for a PD patient, such care is poorly 
developed.8
Therefore, there was a need for patients, caregivers, 
patient organizations, and social authorities to organize a 
special care unit for PD patients in need of permanent care 
with specially trained and interested staff. Such a specialized 
PD care unit for permanent stay was launched in 2004 and, 
to our knowledge, no such unit was then currently existing 
in Europe. The organization and launching of the unit was 
preceded by negotiations and agreements between local 
health and social care authorities, a housing company, and 
the Swedish Parkinson Disease Organization leading to joint 
liability for lodging, caring, and medical health services. We 
report here the general design, implementation, and results 
since starting five years ago.
Methods
The Parkinsonism permanent care unit is situated in the center 
of Täby, a suburb of Stockholm. Patients with a diagnosis of 
Parkinsonism living within the Stockholm catchment area 
of about 2,020,000 inhabitants are eligible to be referred 
to the unit. Referred patients are carefully assessed by two 
specially trained nurses, as well as representatives from 
the Stockholm social care authorities, in order to assess the 
patient’s needs and grant a permit for permanent care for 
the patient before admission. Referrals are issued by physi-
cians or representatives of social care authorities with the 
prerequisite that the patient has intense medical and caring 
needs and, due to these, is no longer able to stay at home or 
at an ordinary nursing home. Patients with severe psychotic 
or behavioral symptoms making it impossible to stay within 
the unit and those at risk of hurting others are the only ones 
who are ineligible.
The PD permanent care unit houses 30 patients, all in their 
own rooms with options to do their own furnishing. There are 
shared dining and living rooms, as well as training facilities 
within the unit. Patients have their meals together at regular 
times, with the option for patients to assist the staff in meal 
preparation in order to maintain normal activities of daily 
living as far as possible.
The staff comprises two nurses and ten assistant nurses 
during the day time, six assistant nurses in the evenings 
until 10 pm, and two at night time. A physician, ie, a move-
ment disorder specialist, visits the PD permanent care unit 
every fourth week and then, according to a preset schedule, 
assesses ten patients each time, as well as on request. There 
is also a geriatrician who visits the PD permanent care unit 
weekly, taking care of general medical problems. Moreover, 
an occupational therapist and a physiotherapist work part-
time on a daily basis at the unit. Before the opening of the 
PD permanent care unit, the staff had been carefully selected 
and then educated for six weeks regarding symptomatology, 
treatment, and care of PD.
A written and continuously reviewed care plan with 
a multidisciplinary approach is made for each patient at 
  admission. This includes recognition of the patient’s medical 
and care status, as well as their social, emotional, cultural, and 
spiritual needs. It also means determining and regularly 
assessing these, and whether the PD permanent care unit is 
the appropriate site of care. Severity of disease is measured 
by Hoehn and Yahr9 and cognition by Mini-Mental State 
  Examination.10 Hoehn and Yahr is an ordinal scale categoriz-
ing the severity of PD from 0 to 5, where 0 represents mild 
disease and 5 very severe disease. All services aim to preserve 
the patient’s quality of life and optimize functionality as 
much as possible, as well as to alleviate problematic symp-
toms whatever their cause, with a supporting and comforting 
attitude from caring staff. Physical, mental, and emotional 
changes in the patient are handled at the PD permanent care 
unit as much as possible, with the possibility of a temporary 
transfer to hospital if there are other illnesses demanding 
specialized investigations or treatments. However, patients 
are to be readmitted to the PD permanent care unit after the 
acute phase is over.
Common nonmotor symptoms are handled individually, 
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Table 1 Treatment guide for some nonmotor symptoms in Parkinson’s disease
insomnia Adjust anti-PD drugs, sleep hygiene, zolpidem, clonazepam
Depression serotonin and noradrenergic reuptake inhibitors, amitryptiline, mirtazapine
rapid eye movement behavior disorder Adjust anti-PD drugs, clonazepam
Fatigue Amantidine, modafinil 
Day time sleepiness Modafinil, selegiline
Psychosis, hallucinations Adjust anti-PD drugs, rivastigmine (mild); atypical antipsychotic drugs, clozapine, quetiapine, 
lanzapine (severe)
cognitive impairment, dementia rivastigmine
constipation Osmotic laxatives, macrogol
Urinary urgency check all drugs, anticholinergic bladder stabilizers, desmopressin for nocturia
impotence Sildenafil, tadafil
Pain Adjust anti-PD drugs, muscle relaxants, paracetamol
restless legs Dopamine agonists
Orthostatic hypotension Adjust anti-PD drugs, increase water and salt intake, fludrocortisone, ephedrine, midodrine
Drooling 0.5% atropine eye drops sublingually, scopoderm patch, botulinum toxin injections into 
salivary glands
excessive sweating Adjust anti-PD drugs, propantheline, propranolol, topical aluminum creams
Abbreviation: PD, Parkinson’s disease.
to the risk of developing or having cognitive failure, another 
common and pervasive complication in late-stage PD is pos-
tural instability. This may create a fear of falling, resulting in 
dependency and immobilization, which might increase the risk 
of constipation and osteoporosis.11 Physiotherapy and exercise 
to improve gait, balance, joint mobility, and transfers are per-
formed to compensate for debilitating disease progression.12
Patients are thoroughly assessed at admission to the PD 
permanent care unit, and screened with laboratory tests on 
a yearly basis thereafter, as well as continuously followed 
up regarding their Parkinsonism, especially their nonmotor 
symptoms. Weight, appetite, stool, and risk of falls,13 as 
well as neuropsychiatric problems and sleep, are followed 
up on a daily basis, with adequate action plans when needed. 
Family members are also incorporated in the patient’s care 
planning and regular family meetings are established, thus 
informing and involving family members and assessing their 
needs and wishes. The study was approved by the regional 
ethics committee of Stockholm.
Results
Over a period of five years, the PD permanent care unit has 
cared for 70 patients (36 men and 34 women) of mean age 
76.6 (range 60–90) years at admission. The mean duration 
of Parkinsonism was 11.8 (range 3–29) years, with a mean 
Hoehn and Yahr of 3.7 (range 1–5) and a mean Mini-Mental 
State Examination of 23.8 (range 10–30, see Table 2). Some 
activities of daily living-dependent factors as surrogate mea-
sures of caregiver burden are also depicted in Table 2.
There were 62 patients with a diagnosis of idiopathic PD, 
three with multiple system atrophy, two with progressive 
supranuclear palsy, one with corticobasal   degeneration, one 
with dementia with Lewy bodies, and one with vascular-
induced Parkinsonism. The initial PD diagnosis was later 
on reassessed and rediagnosed as multiple system atrophy 
in two cases and dementia with Lewy bodies in one case. 
The mean daily levodopa dose was 739 (range 300–1200) 
mg, with 16 patients having additional therapy with a 
catechol-O-methyl transferase inhibitor, 14 patients with a 
monoamine oxidase B inhibitor, 12 patients with a dopamine 
agonist, one patient with Duodopa®, and three with deep 
brain stimulation. The mean duration of stay was 26.9 (range 
1–58) months, where five patients moved out from the PD 
permanent care unit for social reasons after a mean length 
of stay of six (range 1–13) months. There were 13 acute 
transfers to hospital due to exacerbation or new onset of 
comorbidity, but none due to Parkinsonism per se. The mean 
annual fatality rate was seven (range 5–8) with pneumonia as 
the most common cause of death. There were no significant 
gender differences for the parameters described (Table 2). 
During the last three years, there has been a waiting list for 
admission of 2.5 months.
Discussion
A specially designed and staffed care unit, exclusively for 
patients with Parkinsonism, appears to fill a need for both 
patients and caregivers, as well as for social and health care 
authorities. Patients are in a complicated chronic/palliative 
state of their disease, which is a prerequisite for being referred 
and accepted to the PD permanent care unit. They are mostly 
elderly patients, with a PD duration of more than ten years, 
and a rather high caregiver burden, as reflected by high 
Hoehn and Yahr scores, a high number of neuropsychiatric 
symptoms and medications, and a need for help in activities Journal of Multidisciplinary Healthcare 2011:4 submit your manuscript | www.dovepress.com
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of daily living, as indicated by the need for a wheelchair and 
help with feeding (see Figure 1).
Parkinsonism was the inclusion criterion, and not only 
that arising from idiopathic PD, because the need for and 
approach to treatment would be the same for all affected 
patients. However, the majority of our patients had a diag-
nosis of idiopathic PD. Only a few patients have been per-
manently discharged from the unit during the first five years 
of the unit’s operation, and those who actually moved out 
from the PD permanent care unit did so for social and not 
medical reasons, mostly in order to be closer to their relatives. 
  However, the vast majority of patients remained at the unit 
until the end of their lives. Surprisingly, there was a rather 
short duration of stay and remaining life span for these 
patients after admission to the unit, despite the fact that they 
had had Parkinsonism for about ten years, but were now in a 
severe stage of disease. Not unexpectedly, the patients dete-
riorated during their stay, having more severe symptoms as 
well as concomitant diseases. Other studies have highlighted 
the complications experienced by PD patients and pointed out 
strategies to maintain symptom control in late-stage PD.14,15 
Even cognitive behavior therapy has been tried in PD patients 
suffering from nonmotor symptoms like depression, fatigue, 
sleep disturbances, or pain, but there are no conclusive results 
of its effectiveness.16 However, to our knowledge, there is 
no such unit as the one described in this paper.
We believe that patients with end-stage Parkinsonism and 
their caregivers are confronted with similar problems and 
needs as those with typical palliative diagnoses, like cancer.17 
However, patients often do not want to identify themselves as 
having a terminal illness with a limited lifespan.18 In general, 
disease survival in PD patients differs between studies. One 
study showed a two-fold increased risk of death, with a mean 
age at death of 82 years,19,20 and another study demonstrated 
survival of PD patients to be similar to that in a control popu-
lation, up to a disease duration of ten years.21 After ten years, 
these rates were followed by a rise in mortality, which could 
explain our figures. It has been shown that, in PD patients 
reaching Hoehn and Yahr Stage III, as in our patients, the 
patient’s survival time is limited.22
The multidisciplinary palliation approach performed by 
our staff is probably beneficial to patients and their caregiv-
ers, as indicated by the low discharge rate of patients from the 
unit. It has also earlier been described that non-neurologically 
educated health care personnel are unfamiliar with PD.23
The well-trained, specialized staff may also temper the 
impact of disease because there have been no acute transfers 
to hospital due to Parkinsonism. A recent study has reported 
that one-third of PD patients are dissatisfied with the way 
their PD was managed during an acute hospital stay.24 In 
contrast, that study also showed that PD patients are hospi-
talized in frequencies ranging from 7% to 29% per year, and 
Table 2 characteristics of patients at the Parkinson’s disease permanent care unit 2005–2009
All (n = 70) Males (n = 36) Females (n = 34)
Mean Mean Range Mean Range
Age (years) 76.6 76.0 60–86 77.2 64–90
Duration of PD (years) 11.79 12.19 3–28 11.35 3–35
Hoehn and Yahr 3.7 3.6 2–5 3.8 1–5
Levodopa (mg) 739 735 300–1100 743 300–1200
Duration at PPcU (years) 26.9 25.4 3–53 28.6 1–58
MMT 23.8 24.1 10–30 23.7 10–30
Falls/year 63 35 19–51 28 18–40
incontinence 57 35 22
Wheelchair 50 27 23
Feeding help 28 15 13
no ADL help 7 3 4
Total ADL help 25 15 10
Antidepressant use 28 10 18
Antipsychotic use 23 9 14
Abbreviations: ADL, activities of daily living; MMT, methylcyclopentadienyl manganese tricarbonyl; PD, Parkinson’s disease; PPcU, Parkinson’s disease permanent care unit.
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that a substantial number of admissions may be prevented. 
In our PD permanent care unit it seems that the number of 
places is adequate with regard to demand, as indicated by 
the small waiting list.
The PD permanent care unit’s work contrasts with that 
performed by families, which is categorized as a simple car-
ing role with adjunctive professional services regularly or on 
demand. The content of the PD permanent care unit is more 
of complex care, continuously under surveillance by trained 
health care professionals, and also often involving advanced 
medical tasks in accordance with the concept of stroke units.25 
Another study has emphasized that the nature of the disease 
will test the skills and coping abilities of everyone involved 
when caring for the PD patient.26 Clinical competence, com-
mitment, and communication are three crucial parameters of 
the work process at the PD permanent care unit. This includes 
confirmation of diagnosis through medical records and ad 
hoc complementary investigations. The emphasis of the ser-
vices is on quality of life. Individual and regular assessment 
of patients, with goal setting and follow-up, is crucial, as is 
the integration of family members into the caring process. 
A constant readjustment to a changing level of ability of the 
patient is important for the Parkinsonism patient. During the 
course of the disease, nutritional requirements often change, 
resulting in body weight gain or loss, which make a regular 
nutritional assessment important because it may affect the 
patient’s quality of life.27 Moreover, common problem areas 
are well considered and handled, including careful observa-
tion for potentially contraindicated drugs, exact timing or 
even temporary cessation of drug administration, monitoring 
of complications due to immobilization, as well as monitoring 
of emerging psychiatric and cognitive dysfunction.
A limitation of our study is that we did not assess the 
impact of the PD permanent care unit on caregivers, ie, if 
they felt supported and/or relieved that their loved one’s 
care was better. Moreover, we have no data on the health 
economic aspects of this model, ie, if it is cost-beneficial 
compared with traditional alternatives, like home care or 
care in a nonspecialized unit.
It is reasonable to believe that when patients are trans-
ferred from home to the PD permanent care unit, many 
aspects of caregiver burden are relieved. These include the 
physical, emotional, and social impact on caregivers, as 
well as the common limitations of personal time, eventu-
ally leading to decreased life space.28 It has been reported 
that caregiver burden increases with increasing disability 
and disease duration.29,30 The PD permanent care unit may 
therefore function as a relief of responsibilities for   caregivers, 
although they are a valuable source of communication and 
are also very familiar with the patient and can help to iden-
tify the patient’s needs.31 This is especially important for 
PD patients, because the symptoms of PD can vary widely 
between doses of medication and the side effects can be 
complex to manage.
Meeting all the needs of patients with Parkinsonism 
in a chronic/palliative state is an important aim of the PD 
permanent care unit. Despite the chronic/palliative state of 
these patients, there are many therapeutic options, with the 
overriding objective to let the patients end their days in a 
professional and comfortable environment. Future studies 
should include assessment of patients’ and caregivers’ quality 
of life and the impact on caregivers’ life. A health-economic 
calculation, including the costs of caregivers, should also be 
integrated in such a study.
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